joel12 schreef op 28 juni 2019 09:31:
dont be so sure Tom. here IS my logic
1) first the drug received already fast-track-designation
2) which provides Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met
the fact that the drug is fast tracked, it means that it fulfills a serious condition and if phase 1/2 which final data will be coming in fall, I believe Proqr could ask for early conditional approval .. which the Phase 3 could solidify or the FDA could revert the approval.
not to forget that SAREPTA received approval for testing its drug in ONLY 12 kids.
1 more item that came in last JMP .. the CEO said the FDA is ready to get approval even if ALLL patients are to develop cataract. that means that even that is not a barrier for Proqr to get approval and as for the efficacy the CEO mentioned 1 person which started to see after only 1 injection .. 15 years after being completely blind.
I think now more than ever that if the results are good in fall, Proqr will get conditional approval, the FDA will not wait another year for many to loose their sight. no safety issue and if it shows as good or better efficacy Proqr will be commercial. thats my thought. EOM